Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 323.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 281,922 shares of the company’s stock after purchasing an additional 215,283 shares during the period. Rockefeller Capital Management L.P.’s holdings in Recursion Pharmaceuticals were worth $1,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares in the last quarter. Wedmont Private Capital increased its holdings in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Recursion Pharmaceuticals by 28.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after acquiring an additional 2,235 shares during the period. Green Alpha Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after acquiring an additional 2,346 shares during the period. Finally, Xponance Inc. increased its stake in shares of Recursion Pharmaceuticals by 22.2% in the 4th quarter. Xponance Inc. now owns 19,163 shares of the company’s stock valued at $130,000 after purchasing an additional 3,480 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $5.50 on Monday. The firm has a market capitalization of $2.21 billion, a PE ratio of -3.59 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The firm’s 50-day moving average price is $6.62 and its 200 day moving average price is $6.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.42) EPS. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Morgan Stanley dropped their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.